Phase II Trial of Methylglyoxal-Bis (guanylhydrazone) (MGBG) in Patients with Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group (ECOG) Study

Abstract Twenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evalu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer investigation 1990-01, Vol.8 (2), p.143-146
Hauptverfasser:	Winter, Jane N., Ritch, Paul S., Rosen, Steven T., Oken, Martin M., Wolter, Janet M., Wiernik, Peter H., O'connell, Michael J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Drug Evaluation Humans Middle Aged Mitoguazone - adverse effects Mitoguazone - therapeutic use Multicenter Studies as Topic Multiple Myeloma - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!